Biophan Technologies, Inc. Biophan’s Patented Innovations Improve Medical Devices 2005 Money Show Michael Weiner, CEO
Mar 31, 2015
Biophan Technologies, Inc.
Biophan’s Patented Innovations Improve Medical Devices
2005 Money Show Michael Weiner, CEO
Biophan Technologies, Inc. (OTCBB: BIPH)
MEDICAL INNOVATION
The United States and most modern countries place a very high value on medical innovation
Once approved in the market, a medical innovation can generate significant wealth for the inventors and for the shareholders of the company(s) bringing the innovation to market
Over the past fifty years, medical innovations have changed the quality of life immensely, and made many large, and small, fortunes
Biophan Technologies, Inc. (OTCBB: BIPH)
PATENTS AND MONEY
U.S. Patents are one of the most potentially valuable financial instruments in the world
Once issued, they provide “the exclusive right to make, use, or sell,” the invention within the United States of America
The “claims” are where the true value lies One claim can be worth as much as $1 billion
(Polaroid vs. Kodak)
Biophan Technologies, Inc. (OTCBB: BIPH)
Enhancements
Once a product is on the market, another series of innovations and enhancements to the core device can create significant additional wealth
Some examples: “demand” pacing enhancement over pacemakers The implantable defibrillator enhancement Communicating pacemakers Implantable insulin pumps Hundreds more, worth BILLION$
Biophan Technologies, Inc. (OTCBB: BIPH)
BIOPHAN’s BUSINESS
Founded with pacemaker inventor Wilson Greatbatch, to make pacemakers safe for use with MRI
Expanded to include $12 billion worth of medical devices that ship with one problem, or another
Problems had not been solved by the medical device manufacturers
Finding, and patenting, a solution, would help patients, and help manufacturers offer a better device
That was the founding idea behind Biophan Without a strong U.S. Patent system, there would be
little incentive to invest money on solutions like this
Biophan Technologies, Inc. (OTCBB: BIPH)
INNOVATIONS IN INNOVATION
Biophan invests shareholder dollars… To discover, patent, and implement Valuable enhancements to multi-billion dollar
device markets Where the resulting innovation can make a major
shift in marketshare, among major industry players, in major industries
Biophan holds 36 issued US patents, and has 72 more pending; plus many international patents
Biophan Technologies, Inc. (OTCBB: BIPH)
Management
Stu MacDonald, VP R&D – formerly VP R&D at J&J division, with a 400 person organization
Jeff Helfer, VP Engineering – formerly Dir. Of Engineering at the same J&J division
John Lanzafame, President, Nanolution Division – former President STS Biopolymers, acquired by Angiotech (ANPI)
Robert Wood, VP Finance, Treasurer, Secretary, and CFO – CPA in public and private firms
Michael Friebe, Ph.D., MRI Scientist & Entrepreneur Andreas Melzer, MD, renowned medical innovator
Biophan Technologies, Inc. (OTCBB: BIPH)
Biophan’s Mission
Enable over $12 billion worth of medical devices shipping annually safe for use with MRI, and imageable. Many are not: Guidewires, catheters, endoscopes, biopsy needles Pacemakers, defibrillators, neurostimulators, drug
pumps (safety issues, also imaging issues), pain control devices
Stents, embolism clips, aneurysm clips, artificial hips, knees, most other orthopedics
Bring other innovations for competitive advantage to biomedical device and pharmaceutical companies.
Biophan Technologies, Inc. (OTCBB: BIPH)
Biophan’s Solutions
MRI Safety: (many products contraindicated) RF filter from Johns Hopkins (heating) “Anti-Antenna” lead design (heating & induced voltages) MRI Safe non-magnetic motor
Nanomagnetic particle technologies Minimize image artifacts Makes catheters, guidewires, stents, etc visible under MRI Contrast agents Drug Delivery
Biophan Technologies, Inc. (OTCBB: BIPH)
PROTECTED, PROTECTED!
Technologies covered by 114 U.S. Patents
36 ISSUED 72 pending or allowed
Owned by Biophan or licensed exclusively to Biophan for the medical market
Plus many International patents
MRI Device Imaging
SE coronal image of 3 aluminum wires (1/32”). Wire (3) is uncoated.
1 2 3
Biophan’s thin-film
nanomagnetic particle
coating technology
provides a controllable,
“magnetic” signal
capable of creating an
image of the coated
device.
#3 is uncoated.
Biophan Technologies, Inc. (OTCBB: BIPH)
Making Stents Imageable
Seeing blockage of stents has required an invasive procedure
Stents imageable under MRI would be competitively advantaged
Nanoset has a nanomagnetic particle, thin film coating
AMRIS, now Biophan-Europe, has a “retrofit” solution
Both solutions are PATENTED!
Biophan Technologies, Inc. (OTCBB: BIPH)
1.5 Tesla MRI Artifacts of Current Stents
Expanded
StentsOriginal size
Crimped
Stents
Cobalt
316L stainless steel
With existing stent
technology, no useful
images can be obtained from within
common stents using
MRI.
Imaging of In-Stent Blood Clots Using Biophan Resonator Technology
1 Tesla Philips NT, head coil, TR=300ms, TE=6ms, FA=40°,
transversal
Cross Sectional Schematic of Stent with blood clot
Video
Biophan’s technology enables imaging of the blood clot within the stent
Resonant Stent Blood Clot
Biophan Technologies, Inc. (OTCBB: BIPH)
Implications
Impact the $5+ billion stent market Help manufacturers make pacemakers,
defibrillators, and neurostimulators safe, and imageable – competitive advantage to our licensees
Make guidewires, catheters, endoscopes, and biopsy needles safe and image compatible
Opens the field of interventional medicine under MRI (currently only X-Ray/Fluoroscopy)
Biophan Technologies, Inc. (OTCBB: BIPH)
Biothermal Battery
Goal: To provide a long-lived electrical power system for implanted medical devices Powered by body heat differential.
Batteries are a $500 million market, sell for $100 to $225 each in the pacemaker, defibrillator and drug pump markets
Sold to same customers who need MRI safety Nanomaterials brings this capability within striking
distance. We hold issued and pending patents
Biophan Technologies, Inc. (OTCBB: BIPH)
Agreement with NASA
Announced on August 17th a deal with NASA Ames Research Center for Nanotechnology to jointly develop the biothermal battery NASA wants technology for their long duration
manned MARS mission for biosensing and miniature therapeutic devices
Biophan gets commercial rights to jointly developed and NASA developed technology
Nanotechnology and materials science advances makes the biothermal battery possible
Non-Magnetic MRI-Safe and
Imageable Greater efficiency Enables precision
20 nm movements Ideal for drug
pumps, cryogenic applications, implantables
Biophan holds worldwide medical distribution rights, + equity
Biophan Technologies, Inc. (OTCBB: BIPH)
Substrate
Polymer Coating
Nanomagnetic layer
Con
trol
led
Mag
netic
Fie
ldDrug bound to NMP carrier
Con
trol
led
Mag
netic
Fie
ld A
Con
trol
led
Mag
netic
Fie
ld B
Particle type ADrug AParticle type BDrug B
Surface Elution on Demand
Biophan Technologies, Inc. (OTCBB: BIPH)
Reloading Drug Eluting Coatings
Substrate
Polymer Coating
Concentration G
radient
Controlled
Magnetic F
ield
Drug Molecules
Drug bound to NMP carrier
Nanomagnetic layer
Biophan Technologies, Inc. (OTCBB: BIPH)
Guided Drug Delivery
Solid tumor
Apply magnetic field to concentrate particles
Modulate field to release drug from particles
Inject NMPs IV,NMP will circulate through the blood stream
Other options for targeting:1 - Direct injection into tumor site2 - Coating NMP with antibodies to target tumor
Biophan Technologies, Inc. (OTCBB: BIPH)
Markets
Medical devices (safe &/or image): $12 billion Battery: $500 million Contrast Agents: $800 million Drug Pumps: $1 billion Drug Delivery: $40 billion Once a deal is underway, patents and annuity
streams can last a long time; We anticipate money on signing, in development;
plus milestones, royalties, high margin components
Biophan Technologies, Inc. (OTCBB: BIPH)
Business Model
Offering our customers competitive advantage Through proprietary solutions that can gain
marketshare for them FDA approval is pursued by the customer Marketing and distribution of the final device is
their responsibility We sell high margin components and develop
annuities for our shareholders
Biophan Technologies, Inc. (OTCBB: BIPH)
Relationship With Boston Scientific
Joint development agreement, originally entered into November, 2003
Recently moved to second and third phase, and has expanded to multiple products
Reached agreement on term sheet, working on final contract phase
Biophan Technologies, Inc. (OTCBB: BIPH)
Summary Financial Information
Share Price (05-9-05): $2.36 52-Week High: $3.50 52 Week Low: $0.46 Shares Outstanding: 74 million Float: 58 million Market Cap: $176 million Average Daily Volume: 1,218,772
Biophan Technologies, Inc. (OTCBB: BIPH)
BIOPHAN (OTCBB: BIPH)
Biophan Technologies, Inc. (OTCBB: BIPH)
Biophan (OTC: BIPH)
We don’t make medical devices; We make them safe, and imageable, for MRI
And other competitive advantages for our customers
Four of our six technologies are based on nanotechnology
WWW.BIOPHAN.COM